Can a new vaccine stop malaria in its tracks?

NCT ID NCT05400746

Terminated ⭐️ VACCINE ⭐️ Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This early-stage trial is testing a new malaria vaccine candidate, called Pfs48/45, in healthy adults aged 18 to 45 in the UK. The vaccine is designed to block the malaria parasite from spreading, and it's given with an adjuvant called Matrix-M to boost the immune response. The study aims to check the vaccine's safety and see how well it triggers an immune response, using different doses to find the most promising approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pfs48/45 malaria vaccine with Matrix-M adjuvant
What this could lead to: If successful, this vaccine could help prevent malaria, a disease that affects millions worldwide, by blocking the parasite's transmission.
What could go wrong: This is an early-phase trial with only 17 participants, so the vaccine may not produce a strong immune response or may have side effects. Further studies are needed to confirm its effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA PLASMODIUM FALCIPARUM

Contacts and locations

Locations

CCVTM, Churchill Hospital, University of Oxford

Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.